Stock Report

Download full stock data and analysis for free Last Updated: 02-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

DiaMedica Therapeutics (DMAC) Key Ratios

Stock Card factsheet share-fund-plan-icon

$6.63

up-down-arrow $0.18 (2.79%)

As on 02-Sep-2026 11:35EDT

Market cap

info icon

$345 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

9.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -100.20 -171.69 --
EBIT -0.97 -31.70 -26.93 -166.28 -190.18
Net Profit -0.97 -31.69 -26.91 -164.40 -191.09
EPS -0.78 -4.97 -6.40 -6.52 1.80
Book Value -- -- 25.60 -0.26 -5.19
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info ----133,972.64----
Net Margin info ----134,079.79----
Return on equity info -55.90-48.52-79.49-67.68-53.27
Return on Capital info -55.47-48.19---67.28-52.84
Return on Assets info -51.08-44.88-60.11-60.84-48.64
Debt to Equity (x) info ----0.000.000.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
-67.28
-52.84
-46.28
-35.81
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-79.49

Lower than Peers by 63.52

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
-79.49
-67.68
-53.27
-46.77
-36.06
Peer Median
-15.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-60.11

Lower than Peers by 48.26

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
-60.11
-60.84
-48.64
-43.77
-34.21
Peer Median
-11.85
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

133,972.64

Higher than Peers by 133,999.70

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
133,972.64
--
--
--
--
Peer Median
-27.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

134,079.79

Higher than Peers by 134,112.47

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
134,079.79
--
--
--
--
Peer Median
-32.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

3.35

Higher than Peers by 3.35

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
3.35
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-100.20

Lower than Peers by 134.17

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
-100.20
--
--
--
--
Peer Median
33.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-26.93

Lower than Peers by 1.68

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
-26.93
-34.10
-26.25
-41.69
-0.62
Peer Median
-25.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-26.91

Lower than Peers by 5.34

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
-26.91
-34.05
-26.12
-41.72
-0.62
Peer Median
-21.58
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-6.40

Lower than Peers by 0.23

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
-6.40
-0.22
-0.12
0.01
0.28
Peer Median
-6.17
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

12.47

Higher than Peers by 15.36

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
12.47
--
--
--
--
Peer Median
-2.89
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
0.00
0.01
0.01
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
0.00
0.00
0.00
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

6.72

Lower than Peers by 2.39

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
6.72
11.81
8.28
19.27
15.61
Peer Median
9.11
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

6.72

Lower than Peers by 2.39

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
6.72
--
--
--
--
Peer Median
9.11
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
--
--
--
-38.66
Peer Median
0.72
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
--
--
--
--
Peer Median
22.75
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.00

Lower than Peers by 0.06

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
0.00
--
--
--
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
--
--
--
1,650.93
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
--
8,737.90
10,105.25
9,080.12
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
-11.41
-9.51
-5.56
-3.06
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

9.49

Higher than Peers by 4.67

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
9.49
6.66
5.71
2.11
1.31
Peer Median
4.83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-0.96

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
-0.96
-9.61
-7.74
-2.86
-0.64
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

345

Higher than Peers by 128

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
DiaMedica Therapeutics (DMAC)
345
--
--
--
--
Peer Median
217
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...